This action comes after the board suspended the licenses of two companies on charges they were treating patients with unapproved weight-loss drugs in January
Both contain the same active ingredient but are approved for different medical conditions
sFRPs have a Netrin-related motif in the C-terminal region, WIF has a WIF domain in the C-terminal region, and both bind to Wnt proteins, thereby inhibiting Wnt signalling
Whether a symptom you are experiencing is expected, whether it warrants a change in plan, and what to do about it are clinical judgments that depend on your other medications, your history and your examination
, , ,
The study is an ongoing, multicentre, randomised, double-blind, placebo-controlled trial involving 1197 participants with stage F2 or F3 fibrosis